DNA Vaccines

Genetically Modified Dendritic Cells Elicit Immune Responses

Published in Gene Therapy Weekly, March 23rd, 1998

DNA-based immunization using melanoma antigens elicited primary cytotoxic T cell responses in vitro; effects were enhanced by cotransfection of cytokine genes.

DNA-based immunization strategies offer an attractive alternative to protein- or peptide-based approaches because they do not require prior knowledge of the patient HLA haplotype or specific T cell epitopes.

Thomas Tuting and colleagues from several institutions evaluated the potential of DNA vaccination for immunotherapy of malignant melanoma in an in vitro vaccine model using dendritic cells (DC) ("Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry